Australia · Delayed Price · Currency is AUD Pro Medicus Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and EBIT grew over 28% year-over-year, driven by record contract wins and expanding cloud-native, full-stack solutions. Major deals in cardiology and pathology, a robust pipeline, and strong margin performance set the stage for accelerated growth in the second half and beyond.
Fiscal Year 2025
-
Record financial results and strong contract wins drove growth, with expanded dividends and a robust pipeline. Strategic investments, new product offerings, and ambitious targets for the next three years were highlighted, while all AGM resolutions passed with strong shareholder support.
-
Record FY25 with revenue up 32%, profit after tax up 40%, and margins at 74%. Secured $520M in new contracts, expanded into cardiology and digital pathology, and maintained 100% renewal rate. Cloud and AI offerings drive competitive advantage.
-
Record first-half results with 31% revenue and 43% profit growth, driven by major new contracts, renewals, and expanding U.S. market share. Margins remain strong, pipeline replenishment is robust, and cloud-based innovation and AI position the business for continued growth.
Fiscal Year 2024
-
Record financial results, major contract wins, and increased dividends highlighted a strong year. Strategic focus remains on the U.S. market, AI, and cloud innovation, with robust governance and high shareholder support for all resolutions.
-
Revenue and profit after tax rose 29.3% and 36.5% year-over-year, driven by record new sales, cloud-based contract wins, and strong North American growth. Margins improved, pipeline remains robust, and the company is expanding into AI and cardiology, with no contract losses reported.